• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
3-Bromo-4-fluorobenzaldehyde
5-Methyl-1,3,4-oxadiazol2(3H)-one
4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride
4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine
3-Pyridinecarboxaldehyde
Ethyl 3 Fluorobenzoate

Vividion Therapeutics officially withdraws $100 million IPO following acquisition by Bayer

firstwordpharmaAugust 23, 2021

Tag: Vividion , VVID , IPO

Vividion Therapeutics withdrew its plans for an initial public offering after announcing earlier this month that it would be acquired by Bayer for up to $2 billion, Renaissance Capital reported.

The company was founded in 2013 and had disclosed plans in June to raise $100 million and list on the Nasdaq under the symbol VVID.


Previous:XELJANZ (tofacitinib citrate) Receives Marketing Authorization in the European Union for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis

Next:Cuba grants emergency approval to second homegrown vaccine

Related News

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

BioPharmaSpec, the leading global Contract Research Organization (CRO) for Discovery and Preclinical Characterization of Biopharmaceuticals, has officially announced three new European facilities.

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Vividion Therapeutics officially withdraws $100 million IPO following acquisition by Bayer | Pharmasources.com

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

PharmaSourcesNovember 15, 2024

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may like
More>>

Extru 25-20 DESKTOP LIPOSOME EXTRUSION EQUIPMENT

Extru 25-20 DESKTOP LIPOSOME EXTRUSION EQUIPMENT
dipotassium trioxotellurate

dipotassium trioxotellurate
1,3-bi-TBS-trans-Calcipotriol

1,3-bi-TBS-trans-Calcipotriol
Alpha Lipoic Acid Sodium

Alpha Lipoic Acid Sodium
Nanoliposomal TN

Nanoliposomal TN
4'-Demethylepipodophyllotoxin

4'-Demethylepipodophyllotoxin
Triporelin

Triporelin
R-LIPOIC ACID SODIUM SALT

R-LIPOIC ACID SODIUM SALT
Sodium Tripolyphosphate

Sodium Tripolyphosphate
 Alpha Lipoic Acid

 Alpha Lipoic Acid

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service